Profile | GDS2987 / GI_19923396-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 157.2 | 78 |
GSM215298 | PASMC_vehicle_rep2 | 167.5 | 79 |
GSM215310 | PASMC_vehicle_rep3 | 181.6 | 80 |
GSM215311 | PASMC_atorvastatin_rep1 | 169.8 | 80 |
GSM215312 | PASMC_atorvastatin_rep2 | 212.8 | 82 |
GSM215313 | PASMC_atorvastatin_rep3 | 182.3 | 80 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 219.1 | 82 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 200.7 | 81 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 185.4 | 80 |
GSM215327 | PASMC_SLx2119_rep1 | 57.6 | 66 |
GSM215328 | PASMC_SLx2119_rep2 | 31.3 | 49 |
GSM215329 | PASMC_SLx2119_rep3 | 40 | 58 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 14.8 | 39 |
GSM215332 | Fibroblasts_vehicle_rep3 | 34.7 | 65 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 17.9 | 43 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 3.9 | 11 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 31.3 | 63 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 23.6 | 57 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 39.8 | 65 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 11.2 | 32 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 16.7 | 43 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 13.5 | 33 |